# Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia

> **NCT01134263** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 715 (actual)

## Conditions studied

- Dengue Fever
- Dengue Hemorrhagic Fever

## Interventions

- **BIOLOGICAL:** Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus
- **BIOLOGICAL:** Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus
- **BIOLOGICAL:** Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus
- **BIOLOGICAL:** Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus
- **BIOLOGICAL:** Placebo: NaCl 0.9%

## Key facts

- **NCT ID:** NCT01134263
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-05
- **Primary completion:** 2012-11
- **Final completion:** 2013-02
- **Target enrollment:** 715 (ACTUAL)
- **Last updated:** 2019-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01134263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01134263, "Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01134263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*